1 Mohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.